Trial Profile
A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Dexamethasone
- Indications Brain metastases; Malignant melanoma
- Focus Therapeutic Use
- Acronyms CheckMate204
- Sponsors Bristol-Myers Squibb
- 24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress
- 12 Oct 2023 According to Bristol Myers Squibb media release, data from this study has been selected for ESMO 2023.
- 10 Nov 2021 Three-years follow-up results published in the Lancet Oncology